{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261651","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.811106+00:00","generated_at":"2026-05-17T00:52:37.686712+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axsome Q3 2025 net product revenue $171M, up 63% YoY; submits sNDA for AXS-05 in Alzheimer's agitation","bullets":["Total net product revenue $171.0M (63% YoY growth); AUVELITY $136.1M (+69%), SUNOSI $32.8M (+35%), SYMBRAVO $2.1M (first full quarter).","Net loss narrowed to $47.2M ($0.94/share) from $64.6M ($1.34/share) in Q3 2024; cash $325.3M.","Submitted sNDA for AXS-05 in Alzheimer's disease agitation (FDA Breakthrough Therapy); plans NDA submission for AXS-12 in narcolepsy in Q4 2025.","Pipeline: Phase 3 trials to initiate in Q4 2025 for AXS-05 (smoking cessation), solriamfetol (pediatric ADHD, MDD+EDS), and AXS-14 (fibromyalgia).","AUVELITY prescriptions ~209k in Q3 (+46% YoY); contracted with third large GPO; payer coverage ~85%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261651","json":"https://secwatch.observer/filing/0001193125-25-261651.json","markdown":"https://secwatch.observer/filing/0001193125-25-261651.md","text":"https://secwatch.observer/filing/0001193125-25-261651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/0001193125-25-261651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:52:37.686712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}